SCHEMBL5137239

SCHEMBL5137239

COc1ccc(NC(=O)c2ccc(C)c(C)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 14/20 0.73
RAB9A P51151 13/20 0.73
SMN1; SMN2 Q16637 7/20 0.73
TP53 P04637 4/20 0.73
ALOX15 P16050 1/20 0.73
CASP3 P42574 1/20 0.67
SENP7 Q9BQF6 1/20 0.67
PLAU P00749 1/20 0.65
KMT2A Q03164 5/20 0.64
MEN1 O00255 3/20 0.64
CYP1A2 P05177 3/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2C19 P33261 2/20 0.64
MAPT P10636 2/20 0.64
KDM4E B2RXH2 2/20 0.64
TDP1 Q9NUW8 1/20 0.64
ALDH1A1 P00352 3/20 0.62
GAA P10253 1/20 0.62
CYP2D6 P10635 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815389 0.88 NPC1 (0.72) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL13947385 0.88 RAB9A (0.69) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL11308986 0.87 RAB9A (0.67) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL4611508 0.86 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TP53CASP3
SCHEMBL22580640 0.85 TDP1 (0.72) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL14825095 0.85 MAPT (0.62) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL6799157 0.85 RAB9A (1.00) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL22580645 0.83 NPC1 (0.66) NPC1RAB9ASMN1; SMN2TP53PLAU
SCHEMBL22580585 0.83 NPC1 (0.66) NPC1RAB9ASMN1; SMN2TP53PLAU
SCHEMBL2622747 0.83 NPC1 (0.72) NPC1RAB9ASMN1; SMN2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807033-B1 TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING NOVEN PHARMA (US) 2016-07-20 EP disclosed
EP-2001467-A2 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE Adolor Corporation (US) 2008-12-17 EP disclosed
WO-2007118151-A2 SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2007-10-18 WO disclosed